Yang Li, Lu Mengji
Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Institute of Virology, University Hospital Essen, University Duisburg Essen, Essen, Germany.
Curr Med Chem. 2018;25(7):802-813. doi: 10.2174/0929867324666170704121800.
Hepatitis B virus (HBV) infection is still a major health problem worldwide. The current available antiviral drugs for the treatment of chronic HBV infection do not achieve satisfactory results. Thus, it is desirable to develop novel anti-HBV drugs based on the recent advances of basic research on molecular biology of HBV. HBV nucleocapsid assembly is now considered as a potential target of anti-HBV therapy. Structural and functional analysis provided essential insight of molecular interaction of the components of HBV nucleocapsid. Prototypes of small molecule modulators of HBV nucleocapsid assembly were developed and partly tested in clinical phase I. In the present review, the recent advances in HBV molecular biology and approach to develop inhibitors for anti-HBV treatment based on the disruption of viral nucleocapsids by either prevention of assembly or induction of misassembly will be summarized. We will discuss the future concepts of anti-HBV treatment based on such new approaches.
乙型肝炎病毒（HBV）感染仍是全球主要的健康问题。目前用于治疗慢性HBV感染的抗病毒药物未取得令人满意的效果。因此，基于HBV分子生物学基础研究的最新进展开发新型抗HBV药物是很有必要的。HBV核衣壳组装目前被认为是抗HBV治疗的一个潜在靶点。结构和功能分析为HBV核衣壳成分的分子相互作用提供了重要见解。已开发出HBV核衣壳组装小分子调节剂的原型，并在I期临床试验中进行了部分测试。在本综述中，将总结HBV分子生物学的最新进展以及基于通过预防组装或诱导错误组装来破坏病毒核衣壳从而开发抗HBV治疗抑制剂的方法。我们将讨论基于此类新方法的抗HBV治疗的未来概念。
